Loading...
Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $73.7K Total Trade · DGFT Verified
Universal Multi Traders is an Indian pharmaceutical exporter with a total trade value of $73.7K across 2 products in 2 therapeutic categories. Based on 44 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Primaquine ($40.7K), Volini ($33.1K), .
Universal Multi Traders is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on July 1, 2017, the company is registered as a micro enterprise under the MSME classification for the financial year 2024-25. Its registered office is located in Nagercoil, Tamil Nadu, India.
The company's export activities are primarily focused on two therapeutic categories: Antimalarial & Antiparasitic (55.1%) and Brand Names & OTC Products (44.9%). The top five products exported include Primaquine ($41K, Rank #5, 2.4% market share) and Volini ($33K, Rank #5, 1.1% market share). Notably, the portfolio concentration is high, with the top five products accounting for 100% of the export value.
Universal Multi Traders operates across 2 therapeutic categories, with Antimalarial & Antiparasitic (55.1%), Brand Names & OTC Products (44.9%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Antimalarial & Antiparasitic
1 products · 55.1% · $40.7K
Brand Names & OTC Products
1 products · 44.9% · $33.1K
Universal Multi Traders exports 2 pharmaceutical products across 2 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Primaquine | Antimalarial & Antiparasitic | $40.7K | 10 | 2.4% | 5 |
| 2 | Volini |
Headquarters, ownership, manufacturing facilities, and key leadership
Universal Multi Traders is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on July 1, 2017, the company is registered as a micro enterprise under the MSME classification for the financial year 2024-25. Its registered office is located in Nagercoil, Tamil Nadu, India.
The company's export activities are primarily focused on two therapeutic categories: Antimalarial & Antiparasitic (55.1%) and Brand Names & OTC Products (44.9%). The top five products exported include Primaquine ($41K, Rank #5, 2.4% market share) and Volini ($33K, Rank #5, 1.1% market share). Notably, the portfolio concentration is high, with the top five products accounting for 100% of the export value.
Universal Multi Traders operates manufacturing facilities in Nagercoil, Tamil Nadu, India. The facilities are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and specializations are not publicly disclosed.
| $33.1K |
| 34 |
1.1% |
| 5 |
Universal Multi Traders exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $73.7K. The top category is Antimalarial & Antiparasitic (55.1% of portfolio), followed by Brand Names & OTC Products (44.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Universal Multi Traders.
Request DemoThe company's leadership includes:
Additional information regarding other key executives, such as the CEO, CFO, and other directors, is not publicly available.
Regulated market presence, emerging market penetration, and geographic strategy
Universal Multi Traders' export data indicates shipments to various countries, including the Maldives. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's export activities are primarily focused on markets where regulatory requirements are less stringent.
The company's export data indicates shipments to the Maldives, suggesting a presence in emerging markets. However, specific details regarding penetration in Africa, Latin America, and Southeast Asia, as well as WHO prequalification status, are not publicly available.
Universal Multi Traders' export activities are concentrated on a limited number of products, with the top five products accounting for 100% of the export value. This high portfolio concentration indicates a focused geographic strategy, potentially reducing diversification and increasing concentration risk. The company's strategic direction appears to be centered on maintaining a niche presence in select markets.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history for Universal Multi Traders is not publicly available. The company's export data does not indicate shipments to the United States, suggesting limited or no engagement with the US market.
There is no publicly available information regarding Universal Multi Traders' WHO prequalification status or EU GMP certificates. The company's export data does not indicate shipments to markets requiring such certifications, suggesting that the company may not hold these certifications.
Universal Multi Traders is registered with the Ministry of Micro, Small, and Medium Enterprises (MSME) as a micro enterprise for the financial year 2024-25. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available.
There is no publicly available information regarding Form 483 observations, warning letters, or import alerts associated with Universal Multi Traders. The company's export data does not indicate any regulatory actions or compliance issues.
Market share comparison, key differentiators, and strategic analysis
Universal Multi Traders operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. The company's export data indicates shipments of products such as Ropark 1mg, Syndopa Plus, Urimax 0.4mg, Tricort 40mg, and Aldactone 25mg to the Maldives. Specific information regarding top competitors in overlapping categories, market share comparisons, and head-to-head analyses is not publicly available.
Universal Multi Traders' key differentiators include a focused product portfolio with a high concentration on a limited number of products, indicating specialization in specific therapeutic areas. The company's export data suggests a niche presence in select markets, potentially allowing for tailored strategies and customer relationships.
Universal Multi Traders' current strategic direction appears to be centered on maintaining a niche presence in select markets, focusing on a limited number of products. The company's export data indicates shipments to markets where regulatory requirements are less stringent, suggesting a strategy that leverages existing capabilities and market access. Future outlook details are not publicly available.
Track record assessment, certifications to verify, and pre-order checks
Universal Multi Traders has a track record of exporting pharmaceutical products, with a total export value of $74K USD across 44 shipments. The company's export data indicates shipments of products such as Ropark 1mg, Syndopa Plus, Urimax 0.4mg, Tricort 40mg, and Aldactone 25mg to the Maldives. Specific information regarding export volume consistency and reliability indicators is not publicly available.
Importers should verify the following certifications when considering Universal Multi Traders as a supplier:
Verification can be conducted by requesting copies of the certificates directly from the company and cross-referencing them with the issuing authorities' databases.
When conducting due diligence on Universal Multi Traders, consider the following steps:
Red flags to watch for include expired or unverifiable certifications, a history of regulatory non-compliance, and inconsistent export records. Recommended pre-order checks involve verifying product quality through samples and assessing the company's ability to meet delivery timelines.
Universal Multi Traders exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Primaquine ($40.7K), Volini ($33.1K). Total export value is $73.7K.
Universal Multi Traders's total pharmaceutical export value is $73.7K, based on 44 verified shipments recorded in Indian Customs (DGFT) data.
Universal Multi Traders exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (55.1%, 1 products), Brand Names & OTC Products (44.9%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
2 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.